Advertisement Cellectis teams up with MD Anderson Cancer Center for cancer immnotherapy - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Cellectis teams up with MD Anderson Cancer Center for cancer immnotherapy

Cellectis, a gene editing company that uses proprietary technologies to develop CAR T-cell products in adoptive immunotherapy for cancer, and The University of Texas MD Anderson Cancer Center have formed a research and development partnership to bring new cellular immunotherapies to patients suffering from different kinds of liquid tumors.

The strategic alliance is aimed at developing new cancer immunotherapies based on Cellectis’ allogeneic chimeric antigen receptor (CAR) platform.

MD Anderson Cancer Center’s leukemia and myeloma teams will partner with Cellectis to bring better treatments to patients suffering with multiple myeloma (MM), acute lymphocytic leukemia (ALL), T-cell acute lymphocytic leukemia (ALL) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).

This partnership will build on MD Anderson’s preclinical and clinical teams in leukemia and myeloma, along with Cellectis’ allogeneic CAR T-cell therapy approach and manufacturing capabilities in order to carry out the development of Cellectis’ candidate products UCARTCS1, UCART22, UCART38 in T-cell ALL and UCART123 in a rare non curable disease BPDCN.

Cellectis has built an allogeneic CAR T-cell method based on gene editing technologies, with an aim to develop off-the-shelf cellular therapies for the treatment of cancer.

Cellectis MD, executive vice president and chief operating officer Mathieu Simon said: "We are extremely proud to have our research teams partnering with MD Anderson as we aim to address treatments for different types of liquid tumors.

"This alliance could potentially drive to 5 clinical developments within a time horizon of 3 years. Together, we are confident that we will quickly bring new therapeutic solutions to patients."